Cargando…
Phase 2 trial of palbociclib and ganitumab in patients with relapsed Ewing sarcoma
BACKGROUND: Ewing sarcoma (EWS) is an aggressive sarcoma with few treatment options for patients with relapsed disease. Cyclin‐dependent kinase 4 (CDK4) is a genomic vulnerability in EWS that is synergistic with IGF‐1R inhibition in preclinical studies. We present the results of a phase 2 study comb...
Autores principales: | Shulman, David S., Merriam, Priscilla, Choy, Edwin, Guenther, Lillian M., Cavanaugh, Kerri L., Kao, Pei‐Chi, Posner, Andrew, Bhushan, Ketki, Fairchild, Grace, Barker, Emma, Klega, Kelly, Stegmaier, Kimberly, Crompton, Brian D., London, Wendy B., DuBois, Steven G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10417097/ https://www.ncbi.nlm.nih.gov/pubmed/37306107 http://dx.doi.org/10.1002/cam4.6208 |
Ejemplares similares
-
Detection of circulating tumour DNA is associated with
inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s
Oncology Group
por: Shulman, David S., et al.
Publicado: (2018) -
Correction: Detection of circulating tumour DNA is associated with inferior outcomes in Ewing sarcoma and osteosarcoma: a report from the Children’s Oncology Group
por: Shulman, David S., et al.
Publicado: (2019) -
Epitope-Specific Mechanisms of IGF1R Inhibition by Ganitumab
por: Calzone, Frank J., et al.
Publicado: (2013) -
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer
por: Yee, Douglas, et al.
Publicado: (2021) -
Adverse prognostic impact of the loss of STAG2 protein expression in patients with newly diagnosed localised Ewing sarcoma: A report from the Children’s Oncology Group
por: Shulman, David S., et al.
Publicado: (2022)